Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?

References

• Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300–9
   PubMed Web of Science ®Google Scholar
• Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720–40
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. London: EMEA, 2012
   Google Scholar
• Jullien D. [Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis]. Ann Dermatol Venereol. 2012;139:S58–67
   PubMed Web of Science ®Google Scholar
• Levin EC, Gupta R, Brown G, et al. Biologic fatigue in psoriasis. J Dermatol Treat. 2014;25:78–82
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21:211–15
   PubMed Web of Science ®Google Scholar
• Sethu S, Govindappa K, Alhaidari M, et al. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz). 2012;60:331–44
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165–78
   PubMed Web of Science ®Google Scholar
• Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72:1947–55
   PubMed Web of Science ®Google Scholar
• Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;9:949–58
   PubMed Web of Science ®Google Scholar
• Adişen E, Aral A, Aybay C, et al. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study. J Dermatol. 2010;37:708–13
   PubMed Web of Science ®Google Scholar
• Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146:127–32
   PubMed Web of Science ®Google Scholar
• Menting SP, van Lümig PP, de Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol. 2014;150:130–6
   PubMed Web of Science ®Google Scholar
• Bito T, Nishikawa R, Hatakeyama M, et al. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br J Dermatol. 2014;170:922–9
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tsuji H, Ishida-Yamamoto A, et al. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40:39–42
   PubMed Web of Science ®Google Scholar
• Meyer MW, Zachariae C, Bendtzen K, et al. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm Venereol. 2012;92:362–4
   PubMed Web of Science ®Google Scholar
• Cozzani E, Burlando M, Parodi A. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study. G Ital Dermatol Venereol. 2013;148:171–4
   PubMed Web of Science ®Google Scholar
• Mahil SK, Arkir Z, Richards G, et al. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol. 2013;169:306–13
   PubMed Web of Science ®Google Scholar
• Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol. 2010;162:780–5
   PubMed Web of Science ®Google Scholar
• Hoffmann JH, Hartmann M, Enk AH, et al. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol. 2011;165:1355–8
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One. 2012;7:e33486
   PubMed Web of Science ®Google Scholar
• Cassano N, Puglisi Guerra A, Malara C, et al. Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. Int J Immunopathol Pharmacol. 2007;20:647–50
   PubMed Web of Science ®Google Scholar
• Puig L. Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios. Br J Dermatol. 2013;168:674–6
   PubMed Web of Science ®Google Scholar
• Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167:658–67
   PubMed Web of Science ®Google Scholar
• Luber AJ, Tsui CL, Heinecke GM, et al. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. J Am Acad Dermatol. 2014;70:525–32
   PubMed Web of Science ®Google Scholar
• Ramirez-Fort MK, Levin AA, Au SC, et al. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol. 2013;31:S63–70
   PubMed Web of Science ®Google Scholar
• Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol. 2011;164:434–41
   PubMed Web of Science ®Google Scholar
• Vender R. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. J Drugs Dermatol. 2011;10:396–402
   PubMed Web of Science ®Google Scholar
• Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64:671–81
   PubMed Web of Science ®Google Scholar
• Clemmensen A, Spon M, Skov L, et al. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2011;25:1037–40
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kalb RE, Blauvelt A, et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol. 2012;67:642–50
   PubMed Web of Science ®Google Scholar
• Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action. Neurology. 1998;51:682–9
   PubMed Web of Science ®Google Scholar
• Bielekova B, Becker BL. Monoclonal antibodies in MS. Mechanisms of action. Neurology. 2010;74:S31–40
   PubMed Web of Science ®Google Scholar
• Jungedal R, Lundkvist M, Engdahl E, et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler. 2012;18:1775–81
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Neurology. 2007;68:977–84
   PubMed Web of Science ®Google Scholar
• Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs. 2009;23:379–96
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Jensen PE, Haghikia A, et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler. 2011;17:1074–8
   PubMed Web of Science ®Google Scholar
• De Vries HS, van Oijen MCH, Driessen RJV, et al. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol. 2010;71:7–19
   Web of Science ®Google Scholar
• Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258–64
   PubMed Web of Science ®Google Scholar
• Chaparro M, Guerra I, Muñoz-Linares P, et al. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:971–86
   PubMed Web of Science ®Google Scholar
• Ordás I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91:635–46
   PubMed Web of Science ®Google Scholar
• Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics. 2009;3:39–49
   PubMedGoogle Scholar
• Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost. 2004;2:1047–54
   PubMed Web of Science ®Google Scholar
• Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594–8
   PubMed Web of Science ®Google Scholar
• Franchini M, Coppola A, Rocino A, et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost. 2013;39:752–66
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Schroder J, Brackmann HH, et al. Environmental and genetic factors influencing inhibitor development. Semin Hematol. 2004;41:82–8
   PubMed Web of Science ®Google Scholar
• Kruse-Jarres R. Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A. Hematology Am Soc Hematol Educ Program. 2011;2011:407–12
   PubMedGoogle Scholar
• Franchini M, Frattini F, Crestani S, et al. Alloantibodies in previously untreated haemophilia A patients: the role of environmental factors. Hematology 2013;18:183–90
   PubMed Web of Science ®Google Scholar
• DeFrates SR, McDonagh KT, Adams VR. The reversal of inhibitors in congenital hemophilia. Pharmacotherapy. 2013;33:157–64
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Personalized medicine: theranostics (therapeutic diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med. 2013;15:201–11
   PubMed Web of Science ®Google Scholar
• ABIRISK. 2012. Available from http://www.abirisk.eu/documents/ABIRISK_brochure.pdf. Accessed January, 2015
   Google Scholar
• Lundkvist Ryner M, Farrell RA, Fogdell-Hahn A. The case for measuring anti-drug antibodies in people with multiple sclerosis. Expert Rev Clin Immunol. 2014;10:697–9
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol. 2005;12:817–27
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104:760–7
   PubMed Web of Science ®Google Scholar
• Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721–7
   PubMed Web of Science ®Google Scholar
• Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:531--8
   Google Scholar
• Vande Casteele N, Compernolle G, Ballet V, et al. Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Chron Colitis. 2012;6:S68, OP11
   Google Scholar
• Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2014. [Epub ahead of print]. doi: 10.1136/gutjnl-2014-307883
   Google Scholar
• Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962–71
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44:774–81
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919–27
   PubMed Web of Science ®Google Scholar
• Guerra I, Chaparro M, Bermejo F, et al. Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease. Curr Drug Metab. 2011;12:594–8
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16:378--85
   PubMedGoogle Scholar
• Khanna R, Sattin BD, Afif W, et al. Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:447–59
   PubMed Web of Science ®Google Scholar
• Hay CRM, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006;133:591–605
   PubMed Web of Science ®Google Scholar
• De Moerloose P, Fischer K, Lambert T, et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia. 2012;18:319–25
   PubMed Web of Science ®Google Scholar